--- title: "Protara Therapeutics Reports 55% Complete Response Rate In Bladder Cancer Study" type: "News" locale: "en" url: "https://longbridge.com/en/news/286589541.md" description: "Protara Therapeutics Inc. reported a 55% complete response rate for TARA-002 in a Phase 2 study for bladder cancer, with favorable safety results. The study showed a 72.4% overall response rate and highlighted the need for effective treatment options. Despite positive data, Protara's stock fell 3.77% to $5.09, reflecting bearish market pressure. The company plans to expand its registrational studies in the coming months." datetime: "2026-05-15T15:36:29.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286589541.md) - [en](https://longbridge.com/en/news/286589541.md) - [zh-HK](https://longbridge.com/zh-HK/news/286589541.md) --- # Protara Therapeutics Reports 55% Complete Response Rate In Bladder Cancer Study **Protara Therapeutics Inc.** (NASDAQ:TARA) reported updated 12-month Phase 2 data for TARA-002 in patients with Bacillus Calmette-Guérin (BCG)-naïve non-muscle invasive bladder cancer (NMIBC), highlighting durable complete response rates and a favorable safety profile. The updated findings from Cohort A of the ongoing open-label ADVANCED-2 study were presented during a poster session at the American Urological Association 2026 Annual Meeting. **• Protara Therapeutics stock is feeling bearish pressure. What’s weighing on TARA shares?** ## **Durable Responses Observed At 12 Months** The dataset included 31 BCG-naïve NMIBC patients, with 29 evaluable for efficacy as of the April 5, 2026, data cutoff. The company said the complete response (CR) rate at any time reached 72.4%, with 21 of 29 patients responding to treatment. At six months, the CR rate stood at 66.7% among 27 evaluable patients. At 12 months, 55% of 20 evaluable patients maintained a complete response. Among responders, the Kaplan-Meier estimated probability of maintaining a CR for six months was 73.1%, with a 95% confidence interval of 52.9 to 93.4. The company also noted that 91.7% of patients maintained their complete response from nine months through 12 months. In addition, four of six re-induced patients achieved a complete response at six months. **Read Also: Protara's Experimental Bladder Cancer Drug Shows Encouraging Results** ## **Investigators Highlight Safety Profile** **Mark Tyson**, professor of urology at Mayo Clinic Phoenix and an investigator in the ADVANCED-2 study, said the data demonstrated strong durability and a favorable safety profile for TARA-002 in BCG-naïve NMIBC patients. Tyson added that the bladder cancer community continues to need effective bladder-sparing treatment options, while also pointing to the therapy's streamlined administration process for physicians and patients. According to the company, most treatment-related adverse events were Grade 1 and transient. No Grade 3 or higher treatment-related adverse events were reported, and no patients discontinued treatment because of side effects. The most commonly reported treatment-related adverse events included dysuria, fatigue and hematuria. ## **Protara Eyes Registrational Study Expansion** **Jesse Shefferman**, CEO of Protara Therapeutics, said the latest results reinforced the company's belief in TARA-002's potential in BCG-naïve NMIBC. Shefferman added that Protara plans to complete enrollment in the registrational BCG-unresponsive cohort of ADVANCED-2 and expects to initiate ADVANCED-3, a registrational study comparing TARA-002 with intravesical chemotherapy, in the second half of 2026. **TARA Price Action:** Protara Therapeutics shares were down 3.77% at $5.09 at the time of publication on Friday, according to Benzinga Pro. Over the past month, TARA has declined about 1.92% versus a 6.3% rise in the S&P 500 and is down roughly 4% year-to-date compared to the index’s 7.8% gain. _Photo by e-crow via Shutterstock_ **Read Also: Trump May Drop $10 Billion IRS Lawsuit In Exchange For 'Weaponization' Fund: Report** ### Related Stocks - [TARA.US](https://longbridge.com/en/quote/TARA.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md) ## Related News & Research - [Medicare is about to change a drug program that held down the cost of premiums. Here's what to know.](https://longbridge.com/en/news/294391519.md) - [Protara Therapeutics (TARA) Projected to Post Quarterly Earnings on Thursday](https://longbridge.com/en/news/285508340.md) - [Protara Therapeutics CEO Jesse Shefferman disposes of 215,687 common shares for $882,156.83](https://longbridge.com/en/news/291457056.md) - [HEDGE FLOW-Hedge fund bets on rising US healthcare stocks near 5-year high, Goldman says](https://longbridge.com/en/news/293938581.md) - [Wall Street warms to healthcare stocks as tech trade faces turbulence](https://longbridge.com/en/news/294948951.md)